| Literature DB >> 35449102 |
Wenbo Shi1, Yaodong Zhang2, Yangkai Xu3, Xianshang Zeng4, Hongjing Fu5, Weiguang Yu6.
Abstract
BACKGROUND: Conversion of a failed proximal femoral nail antirotation (PFNA) to a total hip arthroplasty (THA) is becoming increasingly universal. However, consensus has not been reached regarding which device (uncemented or hybrid THA) to use. The aim of this retrospective study was to compare the clinical outcomes of the conversion of failed PFNAs to uncemented versus hybrid THAs in the elderly population.Entities:
Keywords: Complication; Conversion; Outcome; Revision; Total hip arthroplasty
Mesh:
Year: 2022 PMID: 35449102 PMCID: PMC9028126 DOI: 10.1186/s12891-022-05323-8
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.562
Manufacturer details of implants
| Stem | Cup | PFNA | |
|---|---|---|---|
| Uncemented THA( | Coraila(uncemented femoral components) | Continuumb(uncemented cup) | Synthes, Solothurn, Switzerland |
| Hybrid THA ( | Exeterc(cemented femoral components) | Continuumb(uncemented cup) | Synthes, Solothurn, Switzerland |
THA Total Hip Arthroplasty, PFNA Proximal Femoral Nail Anti-rotation
aDePuy, bZimmerBiomet, Warsaw, IN, USA, cStryker
Fig. 1Flow diagram exhibiting methods for the identification of study population to evaluate the clinical outcomes of the conversion of failed PFNAs to uncemented or hybrid THAs in the elderly population
Patient characteristics at baseline between cohorts
| Variable | Uncemented THA ( | Hybrid THA ( | |
|---|---|---|---|
| Age (years) | |||
| Median (range) | 66.4(65–71) | 66.7(65–72) | 0.206 |
| Sex, no. % | 0.909 | ||
| Female | 55(47.4) | 56(46.7) | |
| Male | 61(52.6) | 64(53.3) | |
| BMI (kg/m2) | |||
| Median (range) | 24.5(16.7–31.3) | 24.2(16.1–32.8) | 0.325 |
| BMD | -3.61 ± 0.72 | -3.64 ± 0.76 | 0.281 |
| Side, no.% | 0.443 | ||
| Right | 58(50.0) | 54(45.0) | |
| Left | 58(50.0) | 66(55.0) | |
| Hip condition prior to conversion, no.% | 0.869 | ||
| Symptomatic | 66(56.9) | 67(55.8) | |
| asymptomatic | 50(43.1) | 53(44.2) | |
| Femoral head size (mm), no. % | 0.945 | ||
| 28 | 23(19.8) | 26(21.7) | |
| 32 | 44(37.9) | 41(34.1) | |
| 36 | 49(42.2) | 53(44.2) | |
| IHFs, AO/OTA, no. % | 0.543 | ||
| 31A1 | 48(41.4) | 45(37.5) | |
| 31A2 | 68(58.6) | 75(62.5) | |
| Charlson comorbidity index at surgery, no. % | 0.717 | ||
| Low | 42(36.2) | 45(37.5) | |
| Medium | 57(49.1) | 60(50.0) | |
| High | 17(14.7) | 15(12.5) | |
| Reasons for conversion, no. % | 0.459 | ||
| Instability | 55(47.4) | 63(52.5) | |
| Mechanical failure | 45(38.8) | 42(35.0) | |
| Both | 16(13.8) | 15(12.5) | |
| Conversion interval (years) | 0.644 | ||
| < 2 | 74(63.8) | 80(66.7) | |
| ≥ 2 | 42(36.2) | 40(33.3) | |
| Follow-up (months) | |||
| Median (range) | 120.2(102–127) | 120.1(101–127) | 0.219 |
THA Total Hip Arthroplasty, BMI Body Mass Index, BMD Bone Mineral Density
Fig. 2Kaplan–Meier survival curve for both cohorts with prosthesis revision for any reason as and an end point
Long-term follow-up functional outcomes
| Month(s) after revision | Uncemented THA ( | Hybrid THA ( | |
|---|---|---|---|
| 1 | 81.2 ± 13.3 | 81.4 ± 12.4 | 0.102 |
| 6 | 83.5 ± 13.5 | 84.2 ± 11.3 | 0.136 |
| 12 | 84.6 ± 14.7 | 84.5 ± 13.2 | 0.213 |
| 24 | 85.6 ± 14.4 | 86.8 ± 12.8 | 0.372 |
| 36 | 87.4 ± 13.0 | 88.4 ± 11.4 | 0.291 |
| 48 | 89.8 ± 9.4 | 90.1 ± 9.2 | 0.106 |
| 60 | 88.9 ± 9.3 | 90.6 ± 9.3 | 0.116 |
| 72 | 86.2 ± 11.2 | 89.3 ± 9.5 | 0.027* |
| 84 | 82.7 ± 12.6 | 87.7 ± 10.7 | 0.015* |
| 96 | 81.5 ± 11.4 | 86.9 ± 11.6 | 0.032* |
| 108 | 80.1 ± 12.7 | 86.3 ± 11.2 | 0.012* |
| 120 | 78.6 ± 13.4 | 85.6 ± 12.1 | 0.017* |
| Final follow-up | 77.4 ± 13.1 | 85.2 ± 12.3 | 0.014* |
THA Total Hip Arthroplasty
*Statistically significant values
Fig. 3The change curve of the mean value of both cohorts of functional outcomes at each follow-up
Long-term follow-up of key THA-related complications
| Variable, No. % | Uncemented THA ( | Hybrid THA ( | |
|---|---|---|---|
| Revision | 23(19.8) | 9(7.5) | 0.006* |
| Aseptic looseninga | 32(27.5) | 17(14.1) | 0.011* |
| Periprosthetic fractures | 27(23.2) | 11(9.1) | 0.003* |
| Dislocation | 5(4.3) | 4(3.3) | 0.695 |
| Intolerable hip pain | 7(6.0) | 3(2.5) | 0.178 |
THA Total Hip Arthroplasty
aoccurred in femoral side
*Statistically significant values
Fig. 4Kaplan–Meier survival curve for both cohorts with prosthesis loosening as an end point
Fig. 5Kaplan–Meier survival curve for both cohorts with periprosthetic fractures as an end point